Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Zhongyu Yuan"'
Publikováno v:
Russian Journal of Non-Ferrous Metals. 63:701-708
Publikováno v:
Physics of Metals and Metallography. 123:1471-1478
Autor:
Hanfang Jiang, Quchang Ouyang, Yongmei Yin, Zhongshen Tong, Kunwei Shen, Zhongyu Yuan, Cuizhi Geng, Yaxin Liu, Guohong Song, Ran Ran, Wei Li, Qing Qu, Meiyu Wang, Luping Meng, Youzhi Tong, Huiping Li
Publikováno v:
European Journal of Cancer. 176:1-12
Proxalutamide is a novel second-generation non-steroidal androgen receptor (AR) antagonist. This study aimed to evaluate the preliminary efficacy and safety of proxalutamide in patients with AR-positive metastatic breast cancer (ARIn this open-label,
Autor:
Yongfu Wu, Ning Zhang, Yan Shi, Zetao Chen, Han Zhang, Jiaqiang Yin, Tao Zeng, Zhongyu Yuan, Ni Li, Yibin Ren, Liqun Cai, Yunzhao Li, Shengzhong Du
Publikováno v:
Exposure and Health.
Autor:
Mengqian Ni, Fang Wang, Anli Yang, Qiong Shao, Cong Xue, Wen Xia, Fei Xu, Xi Lin, Jiajia Huang, Xiwen Bi, Ruoxi Hong, Meiting Chen, Qiufan Zheng, Kuikui Jiang, Xinhua Xie, Jun Tang, Xi Wang, Zhongyu Yuan, Shusen Wang, Yanxia Shi, Xin An
Publikováno v:
Cancer Medicine.
Autor:
Jie Hou, Guangying Zheng, Lu Han, Zhenyu Shu, Haochu Wang, Zhongyu Yuan, Jiaxuan Peng, Xiangyang Gong
Publikováno v:
Journal of Nuclear Cardiology.
Autor:
Jiaxuan Peng, Wei Wang, Qiaowei Song, Jie Hou, Hui Jin, Xue Qin, Zhongyu Yuan, Yuguo Wei, Zhenyu Shu
Publikováno v:
Academic Radiology.
Publikováno v:
IEEE Transactions on Instrumentation and Measurement. 71:1-13
Autor:
Yanxia Shi, Ying Lin, Kuikui Jiang, Xin An, Heng Huang, Jian-Li Zhao, Zhongyu Yuan, Xiwen Bi, Wen Xia, Lehong Zhang, Zhiyong Wu, Fei Xu, Xin Hua, Ruoxi Hong, Ying Guo, Cong Xue, Yong-Yi Zhong, Yuan-Qi Zhang, An-Qing Zhang, Xin-Mei Liu, Jia Jia Huang, Shusen Wang
Publikováno v:
Clinical Cancer Research. 28:637-645
Purpose: There is no research evidence demonstrate which is the better partner strategy, endocrine therapy or chemotherapy, to combine with anti-HER2 therapy as the first-line management of hormone receptor (HR)-positive (HR+) and HER2-positive (HER2
Autor:
Jianli Zhao, Zhixian Sun, Yunfang Yu, Zhongyu Yuan, Ying Lin, Yujie Tan, Xiaohui Duan, Herui Yao, Ying Wang, Jieqiong Liu
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e006514
BackgroundImmune checkpoint inhibitors (ICIs)-based therapy, is regarded as one of the major breakthroughs in cancer treatment. However, it is challenging to accurately identify patients who may benefit from ICIs. Current biomarkers for predicting th